Development of Copper-Catalyzed Azide-Alkyne Cycloaddition for Increased in Vivo Efficacy of Interferon [Beta]-1b by Site-Specific PEGylation

The development of protein conjugate therapeutics requires control over the site of modification to allow for reproducible generation of a product with the desired potency, pharmacokinetic, and safety profile. Placement of a single nonnatural amino acid at the desired modification site of a recombin...

Full description

Saved in:
Bibliographic Details
Published inBioconjugate chemistry Vol. 23; no. 10; p. 2087
Main Authors Nairn, Natalie W, Shanebeck, Kurt D, Wang, Aijun, Graddis, Thomas J, VanBrunt, Michael Pete, Thornton, Kenneth C, Grabstein, Kenneth
Format Journal Article
LanguageEnglish
Published Washington American Chemical Society 17.10.2012
Subjects
Online AccessGet full text

Cover

Loading…